乳头状甲状腺癌差异表达基因的筛选及生存分析

窦龙涛; 庄振; 刘玲; 周永维; 李晶; 张红梅

doi:10.16098/j.issn.0529-1356.2020.01.009

PDF(4988 KB)

解剖学报 ›› 2020, Vol. 51 ›› Issue (1) : 51-57. DOI: 10.16098/j.issn.0529-1356.2020.01.009

肿瘤生物学

乳头状甲状腺癌差异表达基因的筛选及生存分析

刘中娇窦龙涛庄振刘玲周永维刘曼李晶张红梅*

作者信息 +

Screening and survival analysis of differentially expressed genes in papillary thyroid carcinoma#br#

#br#

LIU Zhong-jiao DOU Long-tao ZHUANG Zhen LIU Ling ZHOU Yong-wei LIU Man LI Jing ZHANG Hong-mei*

Author information +

文章历史 +

摘要

目的利用生物信息学方法筛选乳头状甲状腺癌（PTC）的关键基因及其所在信号通路，探讨其致癌机制。方法从基因表达综合数据库（GEO）的两个测序平台的7个GSE芯片中获得PTC和癌旁组织样本的数据。首先利用R语言分别筛选出两个测序平台样本的差异基因，然后通过Metascape和STRING对差异基因进行生物学功能、信号通路分析和蛋白质-蛋白质相互作用分析,最后利用Cytoscape 3.5.1软件筛选出关键基因。结果两个测序平台的样本求交集共获得302个差异表达基因，其中149个基因上调，153个基因下调，利用Cytoscape 3.5.1软件筛选出15个关键基因，其中12个关键基因位于细胞外基质受体相互作用信号通路中。利用UALCAN数据库对15个关键基因进行生存分析，其中4个基因的表达水平变化与患者的生存时间紧密相关。结论利用生物信息学技术对来自7个PTC基因芯片数据集的信息进行分析，弥补了小样本结果的不一致性，提高了结果的可靠性和稳定性，并且筛选出了15个关键基因，发现了细胞外基质受体相互作用信号通路在甲状腺癌的发生发展中的重要作用。

Abstract

Objective Bioinformatics method was used to analyze gene expression microarrays of papillary thyroid cancer (PTC) and adjacent tissues. The key genes of PTC and their signal pathways were screened to understand their carcinogenic mechanisms. Methods Data on PTC and paracancerous tissue samples were obtained from seven GSE series on two sequencing platforms in the Gene Expression Omnibus Database(GEO).Firstly, the differential genes of the two sequencing platform samples were screened by R language. Then biological function, signal pathway analysis and protein-protein interaction analysis were performed on differential genes by Metascape and STRING. Finally, the key gene were selcected by Cytoscape 3.5.1 software. Results A total of 302 differential genes were obtained from the intersection of the two sequencing platform samples, of which 149 genes were up-regulated and 153 genes were down-regulated. Using the Cytoscape 3.5.1 software to screen out 15 key genes, 12 of them are involved in the extracellular matrix receptor interaction signal pathway. Survival analysis of 15 key genes was performed using the UALCAN database, and the changes in the expression levels of 4 genes were closely related to the survival time of patients. Conclusion This study uses bioinformatics technology to analyze the data from seven PTC gene chips, making up for the inconsistency of small sample result and improving the reliability and stability of the result . In addition, 15 key genes are screened out and found that the matrice extracellulaire receptor interactions pathway plays an important role in the development of thyroid cancer. The result of this experiment provides guidance for the further study of PTC molecular mechanism, diagnosis and screening of prognostic molecular markers.

导出引用

刘中娇窦龙涛庄振刘玲周永维刘曼李晶张红梅. 乳头状甲状腺癌差异表达基因的筛选及生存分析[J]. 解剖学报. 2020, 51(1): 51-57 https://doi.org/10.16098/j.issn.0529-1356.2020.01.009

LIU Zhong-jiao DOU Long-tao ZHUANG Zhen LIU Ling ZHOU Yong-wei LIU Man LI Jing ZHANG Hong-mei. Screening and survival analysis of differentially expressed genes in papillary thyroid carcinoma#br#

#br#

[J]. Acta Anatomica Sinica. 2020, 51(1): 51-57 https://doi.org/10.16098/j.issn.0529-1356.2020.01.009

中图分类号： R736.1

参考文献

［1］ Davies L, Welch HG.Current thyroid cancer trends in the United States［J］. JAMA Otolaryngol Had Neck Surg, 2014, 140（4）: 317-322.

［2］ Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cance ［J］. BMJ, 2014, 348: g3045.

［3］ Nix P,Nicolaides A, Coatesworth AP. Thyroid cancer review1: presentation and investigation of thyroid cancer［J］. Int J Clin Pract, 2005, 59(11):1340-1344.

［4］ Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay ［J］. Cancer, 2014, 120(23): 3627-3634.

［5］ Lalami Y, Awada A. Recurrent thyroid cancer: a molecular-based therapeutic break -through ［J］. Curr Opin Oncol, 2011,23(3): 235-240.

［6］ Gao M, Zheng XQ. Thyroid cancer over the past decade and the next decade ［J］. Chinese Journal of Clinical Oncology, 2018, 45(1): 2-6. (in Chinese)

高明, 郑向前. 甲状腺癌过去与未来十年［J］. 中国肿瘤临床, 2018,45(1):2-6.

［7］ Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy［J］. Lancet, 2005,365(9458): 488-492.

［8］ Guarino V, Faviana P, Salvatore G,et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness ［J］. J Clin Endocrinol MeTab, 2005,90(9): 5270-5278.

［9］ Guba?a E, Wiench M, Oczko-Wojciechowska M,et al. Gene expression analysis by DNA microarray in papillary thyroid cancer. Endokrynol Pol ［J］. Endokrynol Pol, 2005, 56(5):752-727.

［10］Hawthorn L, Stein L, Varma R, et al. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma ［J］. Head Neck, 2004, 26(12): 1069-1083.

［11］Lamba Saini M，Bouzin C，Weynand B, et al. An appraisal of proliferation and apoptotic markers in papillary thyroid carcinoma: an automated analysis ［J］. PLoS One, 2016, 11(2): e0148656.

［12］da Silveira Mitteldorf CA, Juliana Moreira, de Sousa-Canavez, et al.FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples ［J］. Diagn Cytopathol, 2011, 39(8): 556-561.

［13］Koo BS, Kim JM, Seo ST, et al.Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma ［J］. Ann Surg Oncol, 2014,21(7):2310-2317.

［14］Zhang KE, Ge SJ, Lin XY, et al. Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis ［J］. Oncol Lett, 2016, 11(3): 1722-1730.

［15］Buergy D, Weber T, Maurer GD, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies ［J］. Int J Cancer, 2009, 125(4): 894-901.

［16］Qiu J, Zhang W, Xia Q, et al. Investigating the mechanisms of papillary thyroid carcinoma using transcriptome analysis ［J］. Mol Med Rep, 2017, 16(5): 5954-5964.

［17］Ito Y,Takano T, Miyauchi A. Apolipoprotein e expression in anaplastic thyroid carcinoma ［J］. Oncology, 2006,71(5-6): 388-393.

［18］Chitikova Z, Pusztaszeri M, Makhlouf AM. Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis ［J］. Oncotarget, 2015, 6(13): 10978-10993.

［19］Zhang S, Wang Y, Chen M, et al. CXCL12 methylation-mediated epigenetic regulation of gene expression in papillary thyroid carcinoma ［J］. Sci Rep, 2017,7:44033.

［20］Law NC, White MF, Hunzicker-Dunn ME. G protein-coupled receptors (GPCRs) that signal via protein kinase A (PKA) cross-talk at insulin receptor substrate 1 (IRS1) to activate the phosphatidylinositol 3-kinase (PI3K)/AKT pathway ［J］. J Biol Chem, 2016, 291(53): 27160-27169.

［21］Takeda M, Mikami T, Numata Y，et al. Yoshiko numata papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression［J］. Am J Clin Pathol, 2013, 139(5): 587-598.

［22］Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. ［J］. Curr Opin Cell Biol, 1998,10(2): 205-219.

［23］Luo A, Yu X, Li G. Differentiation-associated genes regulated by c-jun and decreased in the progression of esophageal squamous cell carcinoma ［J］. PLoS One, 2014, 9(5): e96610.